NovaBay Pharma (NBY) Tops Q4 EPS by 10c

NovaBay Pharma (NYSE: NBY) reported Q4 EPS of ($1.26), $0.10 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.16 million.

Cash, cash equivalents and short-term investments were $2.4 million as of December 31, 2015, compared with $5.4 million as of December 31, 2014.

For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance